Clinical Trial Update: Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria [Phase 2]

View source ↗

Summary

A Phase IIb study by Curacle evaluating CU01-1001 for 24 weeks in adults with type 2 diabetes and albuminuria; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• CU01-1001

Snippet

Sponsor: Curacle Co., Ltd. | Conditions: Diabetic Nephropathies | Phase 2 | Status: COMPLETED